Effect of tiotropium on lung function decline in early-stage of chronic obstructive pulmonary disease patients: Propensity score-matched analysis of real-world data

International Journal of COPD

Volumn 10, Issue 1, 2015, Pages 2185-2192

  Lee, Ha Youn ^a,b   Choi, Sun Mi ^a,b   Lee, Jinwoo ^a,b   Park, Young Sik ^a,b   Lee, Chang Hoon ^a,b   Kim, Deog Kyeom ^b,c   Lee, Sang Min ^a,b   Yoon, Ho Il ^b,d   Yim, Jae Joon ^a,b   Kim, Young Whan ^a,b   Han, Sung Koo ^a,b   Yoo, Chul Gyu ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Boramae Hospital   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Chronic obstructive pulmonary disease; Lung function decline; Tiotropium

Indexed keywords

TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION DECLINE; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDY; SPIROMETRY; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOUTH KOREA; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT ACUITY; PROGNOSIS; PROPENSITY SCORE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPUBLIC OF KOREA; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84945194059     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S91901     Document Type: Article

References (20)

1. Committe GE. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2015. Available from: http://www.goldcopd.org. Accessed September 11, 2015.
2. Wise RA. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med. 2006;119:4-11.
3. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
4. Tashkin DP, Celli BR, Decramer M, Lystig T, Liu D, Kesten S. Efficacy of tiotropium in COPD patients with FEV1 $60% participating in the UPLIFT® trial. COPD. 2012;9:289-296.
5. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-1178.
6. Bridevaux P-O, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz J-M, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63:768-774.
7. Society AT. Standardization of spirometry, 1994 update. Am Respir Crit Care Med. 1995;15:1107-1136.
8. Morris JF. Spirometry in the evaluation of pulmonary function. West J Med. 1976;125:110-118.
9. Perkins SM, Tu W, Underhill MG, Zhou XH, Murray MD. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2000;9:93-101.
10. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
11. Chen Z, Dunson DB. Random effects selection in linear mixed models. Biometrics. 2003;59:762-769.
12. Cerveri I, Corsico AG, Grosso A, et al. The rapid FEV1 decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study. COPD. 2013;10:55-61.
13. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44: 1521-1537.
14. Incorvaia C, Russo A, Foresi A, et al. Effects of pulmonary rehabilitation on lung function in chronic obstructive pulmonary disease: the FIRST study. Eur J Phys Rehabil Med. 2014;50:419-426.
15. Leidy N, Sexton C, Jones P, et al. Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diary. Thorax. 2014;69(5):443-449.
16. Celli BR. Predictors of mortality in COPD. Respir Med. 2010;104: 773-779.
17. Hoesein FAM, de Hoop B, Zanen P, et al. CT-quantified emphysema in male heavy smokers: association with lung function decline. Thorax. 2011;66:782-787.
18. Washko GR. Rate of decline in FEV1: is emphysema the culprit? Am J Respir Crit Care Med. 2012;185:2-3.
19. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008; 178:332-338.
20. Lee JS, Kim SO, Seo JB, et al. Longitudinal lung volume changes in patients with chronic obstructive pulmonary disease. Lung. 2013;191:405-412.